Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design

NEW! Test-Time Scaling for De Novo Antibody Design
Read our technical reportNEW! Test-Time Scaling for De Novo Antibody Design
Read our technical reportNabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design